COVID-HIG is a plasma-derived therapy being developed for the treatment of Covid-19. Credit: Viktor Forgacs on Unsplash.

A Phase III clinical trial, INSIGHT-012, has launched to assess hyperimmune globulin products, including Emergent BioSolutions’s COVID-19 Human Immune Globulin (COVID-HIG), to potentially treat adult patients at risk of disease progression.

COVID-HIG is a plasma-derived therapy intended for outpatients who are at increased risk of developing severe disease, including people aged 55 years and above and immunocompromised patients aged 18 years and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Also called OTAC, INSIGHT-012 is a randomised controlled trial funded by the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID).

It will test the safety and efficacy of hyperimmune globulin products obtained from plasma of Covid-19 patients who have recovered and developed neutralising antibodies to the SARS-CoV-2 virus.

A total of nearly 800 participants will be enrolled at sites in the US and other countries globally.

Subjects across all trial arms will be given infusions of placebo or one of two hyperimmune globulin products, including Emergent’s COVID-HIG, plus standard of care.

The aim is to determine if anti-SARS-CoV-2 hyperimmune globulin administered at the onset of symptoms can offer a fast increase in the natural, and probably delayed, antibody response to the virus.

This mechanism is expected to mitigate the risk of more serious disease and death.

Emergent BioSolutions senior vice-president and therapeutics business unit head Dr Laura Saward said: “Treatment with COVID-HIG earlier in the Covid-19 disease course offers a window of intervention when viral replication is extensive but natural antibody response hasn’t been generated yet.

“This earlier intervention has the potential to improve patient outcomes and keep people out of the hospital.”

Being a polyclonal product containing a variety of antibodies, COVID-HIG could offer other benefits against SARS-CoV-2 variants of concern as shown by in vitro testing, Saward added.

In October 2020, Emergent announced the start of another NIAID-funded Phase III trial, INSIGHT-013, to analyse COVID-HIG to potentially treat hospitalised patients with Covid-19.